Walter and Eliza Hall Institute of Medical Research

Genentech, Inc.

Abbvie Inc.

Abbott Laboratories Corporation

Novartis Ag

Les Laboratories Servier

Les Laboratoires Servier

Guillaume Laurent Lessene

Jonathan Bayldon Baell

Andrew J Souers

Keith G Watson

John A Flygare

Steven Elmore

Wayne J Fairbrother

Brad E Sleebs

Chudi Obioma Ndubaku

Andrew M Petros

Danette Dudley

Chinh Thien Bui

Le Wang

Zhi-Fu Tao

Antony Wilks Burgess

George A Doherty

Xilu Wang

Michael D Wendt

Milan Bruncko

Gary T Wang

Aaron R Kunzer

Gerard M Sullivan

Hong Ding

Olivier Geneste

Xiaohong Song

Lisa A Hasvold

William J McClellan

Robert A Mantei

Cheol-Min Park

Laura A Hexamer

Yujia Dai

Michael F T Koehler

Dale Porter

Maïa Chanrion

Chang H Park

Peter Colman

Peter Edward Czabotar

Brian John Smith

George Nikolakopoulos

Carl Steven Rye

Steven W Elmore

Brad Edmund Sleebs

Danette A Dudley

Kurt Deshayes

Xiahong Song

Geoffrey Lindeman

Jane Visvader

Ensar Halilovic

Ana Leticia Maragno

Francesca Walker

Helen Witchard

François Vaillant

Elisabetta Marangoni

Delphine Merino

James Whittle

Hiroshi Maruta

Maia Chanrion

Peter Malcom Colman

Michael FT Koehler

A combination comprising a MCL-1 inhibitor and a taxane compound, and compositions and uses thereof.

Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof

The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof.

Anti-cancer agents

In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X, X, X, X, R, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xproteins.

Compounds and methods of use

The present invention relates to chemical compounds of formula (I) and methods for their use and preparation. In particular, the invention relates to substituted pyrazolo[3,4-d]pyrimidine based compounds which can be used in treating proliferative disorders, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds. 

Protein kinase inhibitors and methods of treatment

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

In one aspect, the present invention provides for a compound of Formula I in which the variable X, X, X, X, Q, A, R, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xproteins.

Heterocyclic compounds and methods of use

The invention relates generally to small molecules that mimic the biological activity of certain peptides and proteins, to compositions containing them and to their use. In particular, the invention relates to compounds of the general formula (I) that mimic the biological activity of BH3-only proteins and are capable of binding to and neutralizing pro-survival Bcl-2 proteins: wherein A, A, B, B, B, X, Z, R, R, Rand t are as described herein. The invention also relates to processes of preparing the benzenesulfonamide compounds that mimic portions of peptides and proteins, and to the use of such compounds in the regulation of cell death and the treatment and/or prophylaxis of diseases or conditions associated with the deregulation of cell death.

Arylsulfonamide compounds

Benzoyl urea derivatives that are alpha helical peptides mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting-moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralizing pro-survival Bcl-2 proteins. Use of benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also described.

Alpha-helical mimetics

Growing community of inventors

Parkville, Australia

Guillaume Laurent Lessene